/

BIVI

BioVie Inc.Closed

1.16−0.04 −3.33%USD

NasdaqCM · as of Oct 14, 16:00 ET · 15m delay

Open

1.20

Prev close

1.20

Day range

1.151.25

52-week range

0.82003.79

Volume

342.60K0.07×

Mkt cap

10.07M

P/E ttm

—

Fwd P/E

-2.04

EPS ttm

-3.05

Div yield

0.00%

Earnings

—

From 52w high

−69.39%

Price Chart

Yahoo Finance · delayed

BIVIOct 13, 2026O 1.30H 1.33L 1.20C 1.20−0.12 (−9.09%)Vol 171.90K

SMA 501.67
SMA 2001.52

1Y change −38.46% since Oct 13, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BIVI BioVie Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −16.67%
1 month: −37.82%
3 months: −24.05%
6 months: −17.81%
Year to date: +3.45%
1 year: −38.46%

Valuation & ownership

Market cap: 10.07M
Enterprise value: 47.52K
P/E (ttm): —
Forward P/E: -2.04
PEG ratio: —
Price / book: 0.85
Price / sales (ttm): —
EV / EBITDA: -0.00
EPS (ttm): -3.05
EPS (forward): -0.5700
Beta (5y monthly): 0.73
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 8.68M
Float: 7.48M
Short % of float: 9.62%
Short ratio (days): 1.95
Held by insiders: 0.49%
Held by institutions: 22.13%
Avg volume (3m): 4.59M
50-day average: 1.67
200-day average: 1.52
52-week change: −38.46%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 31.1
vs 50-day SMA: −28.19%
vs 200-day SMA: −20.80%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 12.46%
Realised vol (20d, ann.): 68.5%
From 52-week high: −68.34%
From 52-week low: +46.34%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

5.26

+353.02% implied

Low 5.00Median 5.26High 5.51

Recommendation trend

Now2 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →trailing twelve months

DES

About BioVie Inc.

Yahoo Finance profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Sector: Healthcare
Industry: Biotechnology
Employees: 13
Headquarters: Carson City, NV, United States
Website: bioviepharma.com
Officers: Mr. Cuong Viet Do M.B.A. President, CEO & Director
Ms. Joanne Wendy Kim C.P.A. CFO, Treasurer & Corporate Secretary
Dr. Joseph M. Palumbo M.D. Executive VP of R&D and Chief Medical Officer
Mr. Clarence N. Ahlem

SEAS

Seasonality · BIVI

2020–2026 · monthly returns

Strongest month Oct +32.24%Weakest month Aug −22.60%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-1.7	21.1	1.4	17.9	-13.9	36.6	-21.6	50.0	-33.3	-23.7			+0.0%
2025	-17.5	-19.4	-26.3	-16.5	27.1	-11.1	-35.1	-74.7	25.0	-7.9	-14.3	-22.7	−94.2%
2024	-17.5	19.2	-57.3	-7.4	-6.9	-12.1	-3.0	-28.5	-56.8	128.3	2.2	-28.6	−84.1%
2023	-34.7	51.7	5.1	-1.1	-26.9	-26.2	9.5	-34.1	9.6	27.9	-58.7	-30.0	−83.8%
2022	-29.6	-1.9	51.8	-21.2	-31.2	-43.4	48.3	67.9	-31.0	69.9	59.3	15.3	+72.7%
2021	93.5	-4.2	-39.8	-9.5	-21.5	23.3	-16.6	-43.6	-16.2	-8.5	5.2	-30.1	−74.0%
2020										-16.2	21.1	79.5	+82.1%

INSD

Insider Activity · BIVI

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 27, 2026	Kim Joanne WendyChief Financial Officer	Purchase at price 2.18 per share.	2.5K	$5.45K
Aug 27, 2026	Palumbo Joseph MOfficer	Purchase at price 2.16 per share.	4.8K	$10.46K
Aug 27, 2026	Chappell Amy Suzon M.D.Director	Purchase at price 2.16 per share.	727	$1.57K
Aug 26, 2026	Do Cuong VietChief Executive Officer	Purchase at price 2.08 per share.	15.2K	$31.64K
Aug 6, 2025	Do Cuong VietChief Executive Officer	Purchase at price 2.91 per share.	5K	$14.55K
Nov 19, 2024	Rogich Sigmund ADirector	Stock Award(Grant) at price 0.00 per share.	32.7K	—
Nov 19, 2024	Berman Richard JayDirector	Stock Award(Grant) at price 0.00 per share.	34.2K	—

13F

Investors Holding BIVI

latest 13F filings of 29 followed managers

Investors holding BIVI
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$248.2K	0.00%	127.92K	+88%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

BIVI

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BIVI

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BioVie Inc.

Seasonality · BIVI

Insider Activity · BIVI

Congress Trades · BIVI

Investors Holding BIVI

Investors Holding BIVI

Congress Trades · BIVI

Insider Activity · BIVI

Seasonality · BIVI

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BioVie Inc.

Earnings & Dividends

News